The Medicines and Healthcare products Regulatory Agency (MHRA) has carried out its largest-ever seizure of unlicensed weight-loss medicines, in the latest indication of increased enforcement activity surrounding the rapidly expanding market for weight-loss treatments and peptide products.

On 28 May 2026, officers from the MHRA’s Criminal Enforcement Unit, supported by Northamptonshire Police, raided a country estate near Northampton. The following day, the MHRA announced that approximately 12,000 doses of unlicensed weight-loss medicines had been recovered.

Two men, both aged 29, were arrested on suspicion of offences under the Human Medicines Regulations 2012. The investigation remains ongoing at this stage.

The scale and nature of the operation provide an important reminder to businesses operating anywhere within the weight-loss, aesthetics and wellness sectors that medicines regulation can carry significant criminal as well as regulatory consequences.

What did the MHRA find?

According to the MHRA, the property is believed to have been used as a large-scale facility for the manufacture, assembly and distribution of unlicensed weight-loss medicines.

The products identified included retatrutide and tirzepatide, together with peptide products. Officers also seized substantial quantities of packaging materials and substances believed to have been intended for use in the manufacture of the products.

The seizure is significant not simply because of its size. It demonstrates the MHRA’s willingness to investigate the infrastructure behind the suspected illegal medicines trade rather than limiting enforcement activity to individual products or sellers.

The MHRA described the raid as the latest in a series of operations targeting the illegal supply of weight-loss medicines.

Unlicensed medicines and the regulatory framework

The increasing popularity of GLP-1 and related weight-loss treatments has created a substantial commercial market. However, high consumer demand does not alter the regulatory framework governing medicinal products.

Under the Human Medicines Regulations 2012, there are extensive controls governing the manufacture, assembly, distribution, sale, supply and advertising of medicinal products.

Businesses and practitioners should therefore be particularly careful about the distinction between a medicine which has been properly authorised for use in the UK and products which are unlicensed, improperly sourced or supplied outside the applicable regulatory framework.

The position can become particularly complex where businesses and practitioners operate across traditional healthcare, aesthetics and wellness services, or where products are promoted online and through social media.

The fact that a substance or treatment is widely discussed or available online does not mean that it can lawfully be manufactured, advertised or supplied in the UK.

Retatrutide highlights the risks

The reference to retatrutide in the latest seizure is particularly noteworthy.

Businesses and practitioners need to understand the regulatory status of the particular product they are dealing with. A product being discussed extensively online, used in research, or promoted internationally should not be assumed to have the necessary UK authorisation.

There are also important distinctions between an unlicensed medicinal product and the off-label use of a licensed medicine. These concepts are sometimes incorrectly treated as interchangeable.

Off-label prescribing may, in appropriate circumstances, form part of legitimate clinical practice. That is very different from the unauthorised manufacture or supply of an unlicensed medicinal product.

For clinics and practitioners, understanding precisely what product is being obtained, where it has come from, and the regulatory basis upon which it is being prescribed or supplied is therefore essential.

This is increasingly a criminal enforcement issue

Perhaps the most important message from the latest operation is that medicines compliance should not be viewed solely as a technical regulatory issue.

The MHRA has its own Criminal Enforcement Unit, an in-house law-enforcement function responsible for tackling medicines crime. Its capabilities include intelligence analysis, online disruption, covert techniques and asset recovery, and it works alongside police and other enforcement agencies in the UK and overseas.

In announcing the latest operation, the MHRA made clear that it intends to target not only individual products but also the infrastructure and networks supporting the illegal trade.

Where suspected offending is identified, businesses and individuals can therefore potentially find themselves dealing with search warrants, seizure of products and electronic devices, interviews under caution and criminal investigations.

Depending upon the circumstances and evidence, investigations into profitable illegal trading may also raise wider financial-crime and proceeds-of-crime issues.

For business owners, directors and practitioners, that represents a very different risk profile from receiving a routine regulatory enquiry.

What does this mean for clinics and businesses?

The overwhelming majority of legitimate clinics and healthcare professionals will be far removed from the type of activity alleged in this case. Nevertheless, the enforcement environment should encourage businesses to review their own governance.

Those supplying or facilitating access to weight-loss treatments should understand exactly where medicines have been sourced, whether suppliers are legitimate and appropriately authorised, the licensing status of the relevant product, and whether appropriate prescribing and dispensing arrangements are in place.

Businesses and practitioners should also review how treatments are advertised.